Free Analysis

Costco's Dividend Discipline: What The Charts Show About Cash Return

EOG Versus Devon: The Shale Comparison That Actually Matters

Chevron's Venezuela Gambit Is A Capital Allocation Bet Worth Owning

Lilly Beyond The GLP-1 Story: The Pipeline The Market Is Undercounting

Medicare coverage changes on GLP-1s dominate the headlines. The non-obesity pipeline is where the next leg of Lilly's multiple sits.

The $29 Million Cloudflare Insider Sell Is Not A Coincidence

A cluster of insiders sold $29M in a two-week window. The pattern, the timing and the valuation make this a signal to watch.

Coinbase's New York Fight Just Escalated The Risk Case

The move to federal court changes the shape of the regulatory risk. The headline is about venue. The substance is about precedent.

AMD Is Finally Pricing Like An AI Winner And Still Has Room

Micron, AMD and Broadcom jumped on the latest demand read. At 41x forward earnings, the valuation finally respects the data, and it is still short of the ceiling.

Five Things The Market Is Missing About Visa's Tempo Play

The Tempo blockchain integration and the AI-agents-as-customers pivot are bigger moves than the market has priced. Here are five specific things changing.

Inside Uber's Autonomous Delivery And Robotaxi Machine

Coco Robotics in San Jose. Lucid on robotaxis. The autonomy roadmap at Uber is no longer a slide. It is a revenue line.

JPMorgan's $38 Billion Oracle Loan Is A Capital Allocation Signal

The bank is closing in on a record $38 billion data centre loan to Oracle. The size is not the story. The balance sheet positioning is.

UnitedHealth's Q1 Beat Changes The Turnaround Timeline

Morgan Stanley flagged the Q1 outperformance. The real signal is the medical loss ratio move, which suggests the reserve build is beginning to release.

Freeport Versus BHP: Which Copper Giant Gets You There First

Both are priced around fair value. Only one has a clear path to re-rating inside the next eighteen months.

Why The Next $300 Million Palantir Deal Does Nothing For The Valuation

The USDA contract and a fresh $300 million win look great in the headline. At 231x trailing earnings and 78x sales, the math tells a different story.

CrowdStrike's 264% ROI Claim Just Reframed The Cyber Trade

A new Forrester study puts Falcon Cloud Security's three-year ROI at 264%. That number changes the unit economics conversation for the entire sector.

AbbVie's $1.4 Billion Capex Bet Is Smarter Than It Looks

The $1.4 billion North Carolina manufacturing campus is not a defensive move. It is an ROIC-positive response to the Humira cliff and the new pain licensing deal.